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AbstrACt
Introduction Immune thrombocytopenia (ITP) is an 
autoimmune condition that may cause thrombocytopenia-
related bleeding. Current first-line ITP treatment is with 
high-dose corticosteroids but frequent side effects, 
heterogeneous responses and high relapse rates are 
significant problems with only 20% remaining in sustained 
remission with this approach. Mycophenolate mofetil 
(MMF) is often used as the next treatment with efficacy in 
50%–80% of patients and good tolerability but can take up 
to 2 months to work.
Objective To test the hypothesis that MMF combined with 
corticosteroid is a more effective first-line treatment for 
immune thrombocytopenia (ITP) than current standard of 
corticosteroid alone. 
Methods and analysis Multicentre, UK-based, open-
label, randomised controlled trial. 
setting Haematology departments in secondary care. 
Participants We plan to recruit 120 patients >16 years 
old with a diagnosis of ITP and a platelet count <30x109/L 
who require first-line treatment. Patients will be followed 
up for a minimum of 12 months following randomisation.
Primary outcome Time from randomisation to treatment 
failure defined as platelets <30x109/L and a need for 
second-line treatment.
secondary outcomes Side effects, bleeding events, 
remission rates, time to relapse, time to next therapy, 
cumulative corticosteroid dose, rescue therapy, 
splenectomy, socioeconomic costs, patient-reported 
outcomes (quality of life, fatigue, impact of bleeding, care 
costs).
Analysis The sample size of 120 achieves a 91.5% power 
to detect a doubling of the median time to treatment 
failure from 5 to 10 months. This will be expressed as 
an HR with 95% CI, median time to event if more than 
50% have had an event and illustrated with Kaplan-Meier 
curves. Cost-effectiveness will be based on the first 12 
months from diagnosis. 
Ethics and dissemination Ethical approval from NRES 
Committee South West (IRAS number 225959). EudraCT 
Number: 2017-001171-23. Results will be submitted for 
publication in peer-reviewed journals.
trial registration number NCT03156452
IntrOduCtIOn
Immune thrombocytopenia (ITP) has an inci-
dence of 2.9/100 000 person-years.1 It is an 
autoimmune condition that may present with 
bleeding and bruising due to a low platelet 
count. In ITP, there is increased consump-
tion and reduced production of platelets due 
to both antibody and cell-mediated autoim-
mune attack of platelets and megakaryocytes 
involving dysregulated autoreactive T and B 
cell lymphocytes.2–5
ITP can be classified according to the 
duration of illness into newly diagnosed 
(<3 months), persistent (3–12 months) and 
chronic (>12 months).6 ITP may also be 
strengths and limitations of this study
 ► First UK multicentre randomised controlled trial  for 
first-line treatment of immune thrombocytopenia.
 ► Tests a pragmatic, cost-effective approach which if 
effective, may be applicable to other autoimmune 
conditions.
 ► The trial includes patient-oriented outcomes by us-
ing validated questionnaires to assess quality of life, 
fatigue, impact of bleeding and care costs.
 ► Option to consent to additional blood samples 
for translational research to maximise scientific 
potential.
 ► The limitations include the open-label design, lack 
of very long-term follow-up and sample size unable 
to detect small differences between treatment arms.
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classified as either primary when it presents in isolation 
or secondary when ITP occurs in the context of an associ-
ated illness or medication.6
ITP is a diagnosis of exclusion and made when the 
platelet count <100×109/L and other causes of thrombo-
cytopenia are excluded by history, examination and labo-
ratory evaluation.6 7
Current first-line ITP treatment is with high-dose 
corticosteroids but this has several downsides. First, 
the majority of patients suffer significant side effects 
including mood swings, difficulty sleeping, weight gain, 
high blood pressure, diabetes, gastric irritation, skin thin-
ning and osteoporosis. A published survey of patients 
with ITP reported 98% had at least one side effect and 
38% stopped or reduced dosage due to intolerable side 
effects.8 In the UK ITP registry, the most frequently 
reported comorbidities were related to corticosteroids 
and correlated with duration of treatment (hypertension 
in 30%, diabetes in 19%).9 The second problem is that 
patients are heterogeneous in their response to cortico-
steroid with some (approximately 20%) not responding at 
all and the majority of others (70%–90%) relapsing when 
the corticosteroids are reduced or stopped.7 10 11Patients, 
who are refractory or relapse (the majority), remain at 
risk of bleeding/bruising, which occasionally can be 
severe including intracranial haemorrhage.12 They often 
receive more corticosteroid with associated side effects. 
Some require hospital admission and expensive rescue 
therapies (eg, intravenous immunoglobulin, Ig for a 70 kg 
patient=£3906). They continue to require frequent blood 
tests and doctor visits and are usually unable to continue 
their normal activities until their illness is controlled. 
Fatigue is also associated with disease activity and can 
be severe.13 Physical factors combine with psychological 
stress through fear of bleeding, need for time off work 
and lifestyle restrictions due to bleeding risk to adversely 
impact quality of life.14 15
First-line treatment for ITP is unsatisfactory but it 
remains unchanged for decades. Although a small 
number of studies have tested alternative approaches, a 
well-tolerated, effective and durable new approach has 
not been conclusively demonstrated. High-dose cortico-
steroid remains the standard first-line treatment recom-
mended in most countries.10
Compared with cancers in haematology, ITP remains 
relatively under-researched. The few trials done in ITP 
have often been funded by pharmaceutical compa-
nies, risking publication bias towards high-cost non-ge-
neric drugs. For example, many ‘cheap’, generic drugs 
commonly prescribed for ITP, such as azathioprine, 
mycophenolate mofetil (MMF) and dapsone, have never 
been tested in randomised controlled trials (RCTs) in 
ITP. In contrast, the more expensive treatments, throm-
bopoietin receptor agonists (TPO-RAs) and rituximab 
have been tested in well-designed adequately powered 
RCTs. The relative rarity (2.9/100 000 person-years), 
non-cancerous nature and rare impact on survival of ITP 
have prevented ITP being a priority for research funding 
in the past. However, this underestimates the profound 
adverse impact a diagnosis of ITP and its treatment can 
have for individual patients, many of whom are young. 
There is also a costly financial impact for the National 
Health Service (NHS) from the healthcare resources 
patients require when their illness is uncontrolled. In 
addition, the problems faced by patients with ITP mirror 
those with other autoimmune conditions which as a group 
are common, affecting 3% of the population. There is an 
urgent clinical need to address this inequality, improving 
first-line treatment for ITP through high quality, inde-
pendently funded research to allow patients with this 
condition access to improvements in care seen in other 
illnesses such as cancer or heart disease.
Current popular options for second-line or subsequent 
treatment include MMF, rituximab, TPO-RA and sple-
nectomy. Splenectomy is an effective treatment (60% 
long-term remission rates) but irreversible and interna-
tional guidelines recommend deferring splenectomy 
for the first 12 months following diagnosis due to the 
chance of spontaneous remission (risk of unnecessarily 
removing a healthy organ).7 11 Surgical operations are 
not popular with patients and there is increasing aware-
ness of the short-term and long-term complications of 
splenectomy including infection, bleeding, arterial and 
venous thrombosis, cancer and relapse.16 The splenec-
tomy numbers performed in the UK has dramatically 
reduced over recent years (UK ITP registry data). Ritux-
imab is a monoclonal antibody treatment which targets 
antibody production by B cells. It is relatively expensive, 
with disappointing long-term remission rates similar to 
placebo.16 TPO-RA stimulate platelet production, are well 
tolerated and effective in the majority17 but at significant 
financial cost, prohibiting widespread use in the UK for 
early treatment (National Institute for Health and Care 
Excellence guidance). A small (n=12) non-randomised 
study using TPO-RA with corticosteroid first line showed 
efficacy but perhaps less than expected.18 By contrast, 
MMF is a widely used second-line agent in the UK due 
to good efficacy (response rates of 50%–80%), safety and 
tolerability profile.19–26 MMF has activity against both 
autoreactive T and B cells and has also shown efficacy in 
refractory ITP including steroid resistance suggesting a 
complimentary mechanism of action.24 It is less expensive 
to the NHS than some other second-line options costing 
approximately £182/year (generic cost) compared with 
costs for average doses of romiplostim (TPO-RA) at 
£25 000/year, eltrombopag (TPO-RA) £20 000/year or 
rituximab at £8000 for a course of 4 infusions (375 mg/
m2 each dose) or £1000 (100 mg each dose). However, 
similar to other second-line therapies, MMF has a rela-
tively slow (up to 2 months) onset of action. In the mean-
time, patients often receive further steroid (to maintain 
a ‘safe platelet count’) and continue to suffer problems 
associated with their illness (see above). Direct feedback 
from patients regarding the difficulties they face in the 
first months following ITP diagnosis has been the primary 
driving force for this clinical trial. Local (Bristol) and 
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national patient groups (ITP support association) have 
been fundamental to the formulation of patient relevant 
priorities for treatment.
rAtIOnAlE
The Flight trial is the first UK, NHS coordinated, pharma 
independent multicentre RCT, testing a ‘common sense/
practical’ new approach using MMF first line instead of 
second line with the aim of preventing the almost inev-
itable first relapse when corticosteroids stop. Patients 
will be randomly allocated to one of two treatment arms, 
either standard of care (corticosteroid alone) or MMF 
combined with corticosteroid with the primary outcome 
of time to treatment failure. By giving patients a stable 
platelet count sooner, we expect to improve other 
outcomes such as quality of life and fatigue. By reducing 
the risk of relapse, patients may also be less likely to 
receive a second course of corticosteroid with associated 
side effects. Potential indirect benefits to the NHS include 
reduced need for rescue treatments, blood tests, hospital 
attendances and admissions and reduced need for high-
cost treatments such as TPO mimetics. However, there will 
be some patients who will be treated with MMF who may 
have been successfully treated with corticosteroids alone 
(10%–30%).7 9 10 Similar to other immunosuppressives, 
MMF may slightly increase infection and cancer risk with 
long-term use (SmPC) In addition, MMF is teratogenic 
and therefore stringent pregnancy prevention is essential 
for men and women taking the drug. This puts the trial 
in equipoise. The trial includes a strategy to reduce and 
stop MMF at 6 months for patients in complete remission 
to prevent unnecessary long-term use.
The choice of this open-label design was made in order 
to allow true patient treatment costs to be calculated 
for the cost-effectiveness analysis, and to deal with the 
complexities of placebo controlling a drug that needed 
titrating at the start and tapering at the end. In addition, 
over encapsulation was only possible for the lower MMF 
dose (250 mg) and the resulting capsule was the largest 
size which would mean most patients taking eight large 
capsules per day in both arms; something that patients 
in Bristol thought would put them off taking part in the 
study. Patients were clear that from their perspective 
that a straight forward open-label design would be pref-
erable and was easier for a new patient to understand 
and consent. In addition, the quotes from two separate 
companies also showed the financial costs of encapsula-
tion to generate a placebo were prohibitively expensive.
This trial proposal has received support and input from 
clinicians and patients nationally (UK ITP forum and ITP 
support association). To ensure objective and meaningful 
outcomes, it will be a multicentre RCT, aiming to recruit 
120 patients (expecting 100 full datasets). Patients will be 
given up to 1 week of corticosteroid prior to randomisa-
tion to enable sufficient time to read information, discuss 
and ask questions with informed consent in an appro-
priate setting. Patients will receive the usual follow-up 
according to clinical need and local policy. Laboratory 
and clinical data will be collected from routine appoint-
ments. In addition, patient-oriented outcomes will be 
recorded at diagnosis, 2, 4, 6 and 12 months using vali-
dated patient questionnaires. Patients are also offered 
consent to additional blood samples for translational 
research studies (time 0 and 2 months).
Primary objective
To compare two first-line treatment pathways for ITP, stan-
dard corticosteroid only versus corticosteroid combined 
with MMF and demonstrate which pathway helps patients 
achieve a stable platelet count sooner, measured as 
survival free from treatment failure (time from randomis-
ation to treatment failure).
MEthOds And AnAlysIs
trial design
A multicentre, open-label randomised clinical trial 
of MMF with corticosteroid as first-line treatment for 
patients with ITP versus the standard care pathway of 
corticosteroids alone as first-line treatment.
Eligibility criteria
Inclusion criteria
Patients >16 years old with a diagnosis of ITP (primary 
or secondary), a platelet count <30×109/L and a clinical 
need for first-line treatment. 
Patients can be recruited at any time after ITP diag-
nosis if they are suitable for first-line treatment (ie, not 
previously or recently treated). Patients can receive up to 
1 week of corticosteroid prior to recruitment to allow time 
to be informed about the trial, with the opportunity to ask 
questions and for consent to be taken during a routine 
specialist clinic appointment if preferred.
Exclusion criteria
Pregnancy and breast feeding (Women of childbearing 
potential require a pregnancy test result within 7 days 
prior to randomisation to rule out unintended preg-
nancy). Patients with HIV, hepatitis B or C, common vari-
able immunodeficiency. Contraindications to MMF or 
corticosteroid (see SmPC) including patients with active 
significant infections, hypersensitivity to MMF, mycophe-
nolic acid or to any of the excipients or active significant 
infection. Patients not capable of giving informed consent 
(eg, due to incapacity). Patients (men and women) 
unwilling to follow contraceptive advice if allocated to 
MMF treatment arm.
study setting
One hundred and twenty patients will be recruited from 
approximately 40 haematology departments of hospitals 
(secondary care) across the UK where patients with ITP 
are treated.
The trial processes will be run by the Centre for Trials 
Research (CTR), Cardiff University and sponsored by 
University Hospitals Bristol NHS Foundation Trust.
 o
n
 5 N
ovem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024427 on 18 October 2018. Downloaded from 
4 Pell J, et al. BMJ Open 2018;8:e024427. doi:10.1136/bmjopen-2018-024427
Open access 
The flight trial opened for recruitment on 26 October 
2017.
rAndOMIsAtIOn
Patients who agree to participate will be randomised to 
MMF with corticosteroid or corticosteroid alone in a 1:1 
ratio using a secure web-based randomisation system 
based at Cardiff CTR. Randomisation will be stratified 
by primary or secondary ITP diagnosis. Due to the large 
number of centres and the small number of patients, 
it will not be sensible to stratify randomisation by study 
centre. However, to ensure an even spread of patients 
across time, randomisation will be blocked using random 
block sizes of 6 and 8 to retain concealment.
trEAtMEnt ArMs
Corticosteroid only pathway figure 1: 1 mg/kg once a day 
prednisolone for 4 days (maximum of 100 mg), 40 mg 
once a day for 2 weeks, 20 mg once a day for 2 weeks, 
10 mg once a day for 2 weeks, 5 mg once a day for 2 weeks 
then 5 mg alternate days 2 weeks then stop*. For the dura-
tion of steroid, patients will get a PPI or H2 antagonist 
to protect against gastric bleeding and appropriate bone 
protection figure 1.
*Dexamethasone 20 mg or 40 mg orally daily for 4 days 
is an alternative option to prednisolone if deemed clini-
cally more appropriate for individual circumstances. 
Corticosteroid +MMF pathway figure 2: 1 mg/kg once a 
day prednisolone for 4 days (maximum of 100 mg), 40 mg 
once a day for 2 weeks, 20 mg once a day for 2 weeks, 
10 mg once a day for 2 weeks, 5 mg once a day for 2 weeks 
then 5 mg alternate days 2 weeks then stop*. For the dura-
tion of steroid, patients will get a PPI or H2 antagonist 
to protect against gastric bleeding and appropriate bone 
protection figure 2.
*Dexamethasone 20 mg or 40 mg orally daily for 4 days is 
an alternative option to prednisolone if deemed clinically 
more appropriate for individual circumstances.
From randomisation (alongside steroid), MMF 500 mg 
two times a day starting dose then increased to 750 mg 
two times a day after 2 weeks if tolerated (no side effects 
or laboratory concerns such as neutropenia) and 1 g two 
times a day after another 2 weeks if tolerated (4 weeks 
after starting). Earlier dose escalation to MMF 1 g two 
times a day can be considered if clinically indicated.
After 6 months of MMF therapy, all patients who 
have remained in complete remission (platelet 
count >100×109/L) will reduce the dose by 250 mg (one 
capsule) each month. The aim is to continue on the 
lowest dose that achieves a haemostatic (safe) platelet 
count (platelet count >30×109/L) and to ensure that 
patients who have gone into a remission do not continue 
to take the drug indefinitely.
In both groups
Any steroid commenced prior to randomisation will be 
deducted from the regimens. Importantly, emergency 
and rescue treatments will be permitted throughout the 
study. These include platelet transfusions, tranexamic 
acid and intravenous Ig. These are known not to impact 
on the natural history of ITP and it is recognised that they 
may be important for patient safety. The use of ‘rescue 
treatments’ will be recorded on the case report form 
(CRF).
In addition, some degree of flexibility of corticosteroid 
dose and duration may be needed for individual patients 
according to comorbidity, tolerability and other factors.
If treatment failure occurs, choice of second-line treat-
ment will be individualised according to patient’s clinical 
circumstances. Further steroid will be given according to 
clinical need.
Primary outcome
Time from randomisation to treatment failure defined 
as a platelet count <30×109/L and a need to commence 
second-line treatment. This will include patients who are 
refractory (platelet count <30×109/L in spite of 2 weeks 
treatment in the steroid arm or platelet count <30×109/L 
in spite of 2 months treatment in the steroid +MMF arm) 
or who initially respond but then relapse (defined clin-
ically as platelet count <30×109/L and need for further 
therapy). Patients with a clinical need to start second-line 
treatment early (within 2 weeks for the steroid only arm 
and within 2 months for the MMF and steroid arm), for 
example, due to significant bleeding, will also be classed 
as treatment failures.
secondary outcomes
1. Medication side effects, toxicity or other adverse events 
(including infection episodes).
2. Bleeding events.
a. Site and type of bleeding.
b. Treatment required for bleeding.
c. Whether hospital admission was required.
d. Whether ITP rescue treatments were needed.
3. Remission rates (platelet count >30×109/L and at least 
twofold increase from baseline); Complete 100×109/L, 
partial 30−100×109/L.
4. Time to relapse and time to next therapy.
5. Cumulative corticosteroid dose.
6. Need for rescue therapies.
7. Need for splenectomy.
8. Socioeconomic costs.
9. Patient-reported outcomes (quality of life, fatigue, im-
pact of bleeding, care costs).
Patients follow-up
Patients will be followed up until the end of the trial 
and for a minimum of 12 months. They will receive the 
usual follow-up according to clinical need and local 
policy. Laboratory and clinical data will be collected 
from routine appointments. In addition, patient-oriented 
outcomes and additional data will be recorded at diag-
nosis, 2, 4, 6 and 12 months using validated patient ques-
tionnaires. Patients are also offered consent to additional 
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Figure 1 Flight treatment pathway: corticosteroid only. FACIT, functional assessment of chronic illness therapy; ITP, immune 
thrombocytopenia; IVIG, intravenous immunoglobulin; MMF, mycophenolate mofetil; NHS, National Health Service; pl, platelet; 
PPI, proton pump inhibitor; TxA2, Tranexamic Acid; QoL, quality of life. 
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Figure 2 Flight treatment pathway: corticosteroid and MMF. ITP, immune thrombocytopenia; IVIG, intravenous 
immunoglobulin; MMF, mycophenolate mofetil; NHS, National Health Service, pl, platelet; QoL, quality of life. 
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blood samples for translational research studies (time 0 
and 2 months).
data collection
Hospital monitoring of platelet levels (FBC) is part of 
routine care for patients with ITP and these data will be 
collected and recorded on the CRF without requiring 
patients to come in for additional samples to be taken. 
These locally collected samples may be collected monthly 
(or less often) for patients believed to be in stable remis-
sion and weekly at lower or declining platelet levels. We 
expect this to allow us to calculate the time in remis-
sion and time to relapse with reasonable accuracy over 
the 12–24 months follow-up period. Other clinical and 
laboratory data needed for the trial endpoints will be 
collected from the medical and electronic records and 
recorded on the CRF. In addition, we will also ask the 
patients to complete questionnaires on fatigue, quality of 
life and bleeding scores at baseline, 2, 4, 6 and 12 months 
(table 1).
Patient-reported outcomes will be captured by the 
following questionnaires:
1. SF36V.2 (Your health & well-being)—quality of life.
2. FACIT-fatigue  (V.4)—fatigue.
3. FACT-Th6 (V.4)—bleeding.
4. ICECAP-A V.2—quality of life.
5. Health economic/resource use questionnaire—per-
sonal and social costs.
Additional optional research blood samples (requiring 
separate consent) will be sent at baseline and 2-month 
follow-up to the Bristol Biobank.
data management
Source documents produced for this trial will be kept in 
the patient’s hospital records and source data will be tran-
scribed into trial-specific CRFs at the end of each patient 
visit. Data recording for this trial will be via a web-based 
system. This is a secure encrypted system accessed by an 
institutional password which complies with Data Protec-
tion Act standards. The database will be stored and regu-
larly backed up on a Cardiff University Server. The CRFs 
will be coded with the study number and will not include 
patients’ names and addresses
Patient and public involvement and engagement
During the trial development, a group of eight patients 
with ITP discussed the study design, burden of outcome 
measure completion to patients and the size of a potential 
Table 1 Time schedule of enrolment, interventions, assessments and visits
Procedures
V0 V1
V2
(two 
months)
V3
(four 
months)
V4
(six months)
V5
(12 months)
V6
12–24 months
Screen
Baseline/
randomisation to 
pathway 1 or 2 Follow-up Follow-up Follow-up Follow-up
Data collection 
from sites
Eligibility assessment x
Randomisation x
Informed consent x
Demographics x
Medical history x x x x x
Physical examination x
Vital signs (incl height and weight) x x x x x
Pregnancy test x
Concomitant medications x x x x x
Standard practice bloods (includes blood sugar 
if applicable)
x x x x x x
Hepatitis B, C and HIV serology x
Immunoglobulins (blood) x x x
Extra blood samples (optional) x x
Dispensing of trial drugs x*
Compliance x
QofL FACT-Th6, V.4 x x x x x x
QofL ICECAP V.2—A measure x x x x x x
QofL SF-36V.2— Health Survey x x x x x x
QofL FACIT-F, V.4, pg 3 (fatigue) x x x x x x
QofL Thrombocytopenia costs questionnaire x x x x x x
Data collection from sites on platelet count and 
treatment
x x x x x x
*MMF and corticosteroid dispensing frequency can follow standard local practice.
MMF, mycophenolate mofetil; QofL, quality of life.
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placebo capsule which they reported could put them off 
getting involved in a trial. They reported that avoidance 
of relapse, early achievement of a stable platelet count, 
reduced overall corticosteroid dose and reduced hospital 
attendances are the most important goals for ITP manage-
ment from their perspective.
We formed a patient advisory group with some of these 
patients and representatives from the ITP association that 
will advise the trial management group (TMG) throughout 
the study. They have commented on all patient-facing docu-
mentation and will be instrumental in disseminating the 
study findings to patient groups and the public.
stAtIstICs And dAtA AnAlysIs
sample size calculation
There are no published clinical data available for MMF 
use first line in ITP as this is a novel approach. We have 
analysed local data on MMF used second line in ITP in 12 
patients which shows an estimated median survival free 
from treatment failure of more than 10 months. We have 
data on 68 who experienced corticosteroids as a first-line 
treatment showing that 70% of them had experienced 
a treatment failure by 12 months and that the median 
survival free from treatment failure was 5.0 months 
(95% CI 3.2 to 6.8). Data for the 12 patients treated with 
MMF second-line therapy have shorter follow-up times, 
with only 5 patients having follow-up beyond 12 months. 
The Cox proportional hazards regression model demon-
strates the 90% CI for the HR to be between 0.13 and 0.59, 
showing that our decision to power this on an estimate of 
a hazard of lower than 0.5 is potentially achievable.
Clinically a doubling in the time to remission was 
thought to be something that the patients would have 
welcomed. Less than that was not thought to be sufficient 
grounds for switching this treatment from second line to 
first line due to the potential for additional toxicity and 
immune suppression in those who may have remained in 
remission with corticosteroids alone.
The sample size of 120 (60 per group) with less than 
5% loss to follow-up achieves 91.5% power to detect a 
doubling of the median time to treatment failure from 5 
to 10 months if the patients are recruited at a steady rate 
or 10 per month for 12 months and all followed up until 
the last patients reaches 12 months follow-up.
statistical analysis
The full statistical analysis will be written into a statis-
tical analysis plan available separately. The analysis will 
produce a Consolidated Standards of Reporting Trials 
diagram for the reporting of clinical trials.
The baseline characteristics of the two groups will be 
tabulated but not tested for statistically significant differ-
ences between the groups.
The primary analysis is by intention to treat. However, 
an investigation of compliance with the treatment 
pathway and compliance with the criteria for changing 
to a second-line therapy will be carried out prior to the 
primary analysis to check the date of the primary event. 
The primary event is the date at which there was a require-
ment for second-line therapy. Where the platelet count 
falls below the level required for this treatment decision, 
the first date at which either symptoms or a blood test 
revealing this event will be used. If a clinician decides to 
use a second-line therapy without a platelet count below 
the criteria, the date of the treatment decision/new 
prescription will be taken to represent that event. The 
results will be expressed as an HR with 95% CI, median 
time to event if more than 50% have had an event and 
plotted as Kaplan-Meier curves.
The primary analysis will contain all patients who are 
randomised for as long as they have been followed up 
or until their first event in a survival analysis using inten-
tion to treat methodology. All patients will be followed 
up to 12 months. In addition, patients who have not had 
an event in the first 12 months postrandomisation will be 
followed until their first event or until the last patient has 
reached the 12-month point—whichever is the sooner 
and included in the analysis until that time accord-
ingly. Sensitivity analyses will include landmark analysis 
or shifting the time line to classify all treatment failures 
before 2 months as at 2 months in order to prevent poten-
tial biases caused by different definitions of treatment 
failure time frames between the two groups.
Analysis of other outcomes will use as full a data set as 
possible and focus on the 12-month data point or area under 
the curve as appropriate and detailed in the analysis plan.
No interim analyses of the main endpoint will be 
supplied to the independent data monitoring committee 
(DMC) due to the short time frame (12 months recruit-
ment) in which all patients will be recruited by the time 
the first patient has completed follow-up. Serious adverse 
event (SAE) rates will be reported on a monthly basis 
to the TMG and the DMC. The DMC could advise the 
chairman of the trial steering committee and chief inves-
tigator if these provide proof beyond reasonable doubt 
that it would be unethical to continue with the trial.
Pharmacovigilance
The collection and reporting of all adverse events is in 
accordance with the Medicines for Human Use Clinical 
Trials Regulations 2004 and its subsequent amendments 
and follows the standard operating procedures of the 
trials unit, Cardiff University CTR.
Seriousness and causality are assessed by participating 
sites and further review of expectedness (based on the 
reference safety information) is conducted centrally on 
behalf of the Sponsor. Events are defined as SAEs, serious 
adverse reactions (SARs) or suspected unexpected SAR 
in line with regulatory definitions on the basis of these 
assessments.
SAEs are reported throughout the treatment period 
up to 6 weeks after cessation of last dose of MMF. SARs 
should continue to be reported until the end of follow-up. 
All deaths and overdoses are reported to the sponsor as 
an SAE and reviewed in line with other events.
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MMF in this trial has a genotoxic and teratogenic poten-
tial and therefore pregnancy is contraindicated. Partici-
pants who are female of childbearing potential or male 
with female partners of equal potential are required to use 
contraception as indicated in the protocol. Pregnancy or 
the pregnancy of a partner occurring while participating 
in the trial is not considered an SAE, however, a congen-
ital anomaly or birth defect is. Pregnancy is reported to 
sponsor and followed up to outcome.
All safety events are reviewed by the TMG on an ongoing 
basis and reported to the trial steering committee for 
oversight. Overall assessment of the safety profile of both 
arms will be included in final reporting and publication.
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